Within the past decade, the role of NLRP3 inflammasome in macrophages in the development of silica-induced pulmonary fibrosis has been well recognized [28]
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
The intake of antibiotics to somehow destroy the intestinal microbiota and the administration of the oligosaccharide lactulose, an osmotic laxative, can be additional methods
Fibroblast activity and collagen synthesis
For example, one patient said her skin feels firmer, and my fine lines are way less noticeable after a few months of GHK-Cu injections
